Categories: India

BRIEF-Nucana Says Data From Nutide:701 Shows Favorable Safety And Tumor Reduction

Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Indianews Syndication

Recent Posts

Kennametal India’s Revenue Grows by 39% in the Quarter Ended March 2026

Bengaluru (Karnataka) [India], May 11: Kennametal India Limited (KIL) reported revenues of ₹4031 million for…

8 hours ago